Analysts have clear opinions on AVRO.
There are 4 analysts on the Wall offering 12 month price targets for Avrobio in the last 3 months. The average price target is $31.67 with a high forecast of $35.00 and a low forecast of $28.00. The average price target represents a 39.58% increase from the last price of $22.69.
AVROBIO, Inc. (AVRO) is followed by 4 analysts on the street.
Debjit Chattopadhyay from H.C. Wainwright rates it a Buy with a target of $35.00.
Similarly, 3 months ago David Nierengarten of Wedbush Reiterated a Buy with a target of $32.00.
The consensus on the street is Strong Buy.
What does AVROBIO, Inc.(AVRO) do ?
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.
AVROBIO, Inc. (AVRO) Insider Trades
Multiple company employees have indulged in significant insider trading. AVROBIO, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):
10%, Atlas Venture Fund X, L.P. : P – Purchase(+$15,000,004) of AVRO in the trading session of 2019-07-19.
Dir Booth Bruce : P – Purchase(+$15,000,004) of AVRO in the trading session of 2019-07-19.
Dir Paige Christopher : S – Sale(-$257,196) of AVROBIO, Inc. in the trading session of 2019-04-05.